The presence of anti-cyclic citrullinated peptide antibody is associated with magnetic resonance imaging detection of bone marrow oedema in early stage rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 65, Issue 1, 2006, Pages 133-134

  Tamai, M ^a   Kawakami, A ^a   Uetani, M ^a   Takao, S ^a   Tanaka, F ^a   Nakamura, H ^a   Iwanaga, N ^a   Izumi, Y ^a   Arima, K ^a   Aratake, K ^a   Kamachi, M ^a   Huang, M ^a   Origuchi, T ^a   Ida, H ^a   Aoyagi, K ^a   Eguchi, K ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GADOLINIUM PENTETATE; IMMUNOGLOBULIN M; RHEUMATOID FACTOR; STROMELYSIN;

ANTIBODY DETECTION; ARTICLE; BONE EROSION; BONE MARROW DISEASE; BONE MARROW EDEMA; CARPOMETACARPAL JOINT; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; EDEMA; FINGER; FOLLOW UP; HAND RADIOGRAPHY; HUMAN; IMAGE ANALYSIS; INTERPHALANGEAL JOINT; MAJOR CLINICAL STUDY; METACARPOPHALANGEAL JOINT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOULNAR JOINT; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEROLOGY; SYNOVITIS; WRIST;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; BONE MARROW DISEASES; EDEMA; HUMANS; MAGNETIC RESONANCE IMAGING; PEPTIDES, CYCLIC;

EID: 29144469245     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.04138     Document Type: Article

References (9)

1. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16:585-91.
2. Arnett EC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatology Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
3. Graffney K, Cookson J, Blades S, Coumbe A, Blake D. Quantitative assessment of the rheumatoid synovial microvascular bed by gadolinium-DTPA enhanced magnetic resonance imaging. Ann Rheum Dis 1998;57:152-7.
4. Reece RJ, Kraan MC, Radjenovic A, Veale DJ, O'Connor PJ, Ridgway JP, et al. Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum 2002;46:366-72.
5. McQueen FM. Magnetic resonance imaging in early inflammatory arthritis: what is its role? Rheumatology (Oxford) 2000;39:700-6.
6. Lassere M, McQueen F, Ostergaard M, Conaghan P, Shnier R, Peterfy C, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Exercise 3: An international multicenter reliability study using the RA-MRI score, J Rheumatol 2003;30:1366-75.
7. Conaghan P, Lassere M, Ostergaard M, Peterfy C, McQueen F, O'Connor P, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Exercise 4: An international multicenter longitudinal study using the RA-MRI score. J Rheumatol 2003;30:1376-9.
8. McQueen FM, Benton N, Perry D, Crabbe J, Robinson E, Yeoman S, et al. Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1814-27.
9. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.